Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | TSHR | P16473 | 2/20 | 0.76 |
| ▸ | THPO | P40225 | 2/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.76 |
| ▸ | GLA | P06280 | 1/20 | 0.76 |
| ▸ | EIF4E | P06730 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | TOP1 | P11387 | 1/20 | 0.76 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.76 |
| ▸ | PNP | P00491 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13352082 | 1.00 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL13320541 | 1.00 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL13320671 | 1.00 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL12901991 | 1.00 | LMNA (0.76) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL15617567 | 0.89 | LMNA (0.61) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL5566208 | 0.88 | LMNA (0.78) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL15155278 | 0.88 | LMNA (0.78) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| SCHEMBL4195683 | 0.88 | LMNA (0.78) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| Ribavirin SCHEMBL28339185 | 0.87 | LMNA (0.90) | LMNASMN1; SMN2ALDH1A1TSHRTHPO | |
| Ribavirin SCHEMBL4064991 | 0.86 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-9504705-B2 | Hepatitis C viral infection treatment using a combination of compounds | ALIOS BIOPHARMA, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9393256-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2016-07-19 | — | — | US | disclosed |
| US-20160137685-A1 | NUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHORAMIDITES | PATEL HASMUKH B (US) | 2016-05-19 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140303113-A1 | HEPATITIS C VIRAL INFECTION TREATMENT USING A COMBINATION OF COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20110306541-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20100129317-A1 | AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL POLYMERASES | SOUTHERN RESEARCH INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| EP-2061316-A2 | AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VARIAL POLYMERASES | Southern Research Institute (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008067002-A2 | AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VARIAL POLYMERASES | SOUTHERN RESEARCH INSTITUTE (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306541-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | LMNA 4253/4885SMN1; SMN2 3552/4885ALDH1A1 308/4885 |
| US-20130243726-A1 | METHODS FOR TREATING HCV | HAVCR2, DHFR, HCCS | LMNA 4426/4885SMN1; SMN2 3614/4885ALDH1A1 220/4885 |
| US-20160137685-A1 | NUCLEOSIDE PHOSPHORAMIDATES AND PHOSPHORAMIDITES | PNP, NTPCR, SLC29A1 | LMNA 3879/4885SMN1; SMN2 2237/4885ALDH1A1 2266/4885 |
| US-20140303113-A1 | HEPATITIS C VIRAL INFECTION TREATMENT USING A COMBINATION OF COMPOUNDS | HAVCR2, SLC10A1, NR1H4 | LMNA 3322/4885SMN1; SMN2 4570/4885ALDH1A1 440/4885 |
| US-20100129317-A1 | AZOLE NUCLEOSIDES AND USE AS INHIBITORS OF RNA AND DNA VIRAL POLYMERASES | RNASEH1, RNASEL, POLR2E | LMNA 739/4885SMN1; SMN2 3616/4885ALDH1A1 2684/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | LMNA 4253/4885SMN1; SMN2 3552/4885ALDH1A1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.